28

2020-02

Strive to Be Industry Leader in Search of Innovative Development Together! Lixin Ding Visited Leading Biopharmaceutical Enterprises

To further strengthen the support and speed up the cultivation of a group of leading biopharmaceutical enterprises with global influence, the Party Working Committee and Management Committee of the park carried out a comprehensive and detailed sorting of biopharmaceutical enterprises in the park and selected a group of leading enterprises with independent brands.

17

2020-02

Suzhou Kintor Obtained Approval to Conduct Clinical Trials for SMO Antagonists in China

On February 17, 2020, National Medical Products Administration officially granted the clinical trials notification to Suzhou Kintor Pharmaceuticals, Inc.(hereinafter referred to as “Suzhou Kintor") and agreed to approve clinical trials to be conducted on the SMO antagonist, GT1708F.

20

2019-12

2019 List of Future Top 100 Medical Enterprises Is Released, Visualizing Enterprise Growth Trajectory by Data

On December 20, 2019, Future Top 100 Medical Enterprises Meeting of 2019 under the theme of “New Life Increment” was kicked off in Beijing· Jiuhua Villa. The meeting focused on multiple factors such as policy environment, technology environment and demanding spaces, provided comprehensive interpretation of the future development trend of health care industry to promote the reform of innovative health care industry.

13

2019-12

Ms. Lu Yan Serves as Kintor's Chief Financial Officer

[Suzhou, December 13, 2019] Kintor Pharmaceutical Limited and its subsidiaries (the "Group") officially announced the appointment of Ms. Lu Yan as Chief Financial Officer who would be responsible for our capital market strategy, financial planning, investor relations and internal controls

25

2019-10

Kintor Pharmaceutical Limited Announces Completion of USD45 Million Financing to Push Global Clinical Development and Industrialization Of New Anticancer Drugs

[Suzhou, China, October 25, 2019] Kintor Pharmaceutical Limited (the parent company of Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor")) and its subsidiaries (the "Group")announced completion of a financing of USD45 million in September 2019, which was a new round of financing after Series C investment of RMB288 million in February 2018. This round of investment was led by the Shanghai Free Trade Zone Fund, followed by Huajin Capital, CCB Technological Innovation Fund, Yicheng Hongtai, Yirongchuang and Guangzhou Chengfa. The original investor, Highlight Medical, also participated in this round of investment.

29

2019-08

How Many Blockbuster Novel Drugs Can Be Produced for Chinese Hair Loss Population of 250 Million?

Recently, a group of data indicating more than 250 million people with hair loss in China has circulated online and caused heated discussion. In fact, hair loss is a common disease worldwide. Under normal circumstances, a healthy person will have nearly a hundred hairs shed naturally every day, and an equal amount of hair will be reborn from the scalp hair follicles. If hair loses faster than growth of newborn hair, there will be hair loss problem, which will affect the aesthetics and mental health.

< 1...242526...28 > proceed page

Kintor